To evaluate the potential of FOXA1 as a biomarker for identifying aggressive forms of prostate cancer, particularly in cases where conventional diagnostic markers are lost.
Key Findings:
FOXA1 showed high sensitivity for prostate adenocarcinoma, even when conventional markers were lost.
FOXA1 remained detectable in many cases of small cell carcinoma of the prostate, which often loses traditional markers.
Positive FOXA1 staining was observed in 76 of 81 primary prostate adenocarcinomas and all 11 metastatic adenocarcinomas.
In small cell carcinoma, FOXA1 expression persisted in 80% of primary cases and 57% of metastatic cases, despite loss of conventional markers.
Interpretation:
FOXA1 may assist in identifying the tissue of origin in metastatic neuroendocrine tumors in patients with a history of prostate cancer, addressing the diagnostic challenges posed by small cell carcinoma.
Limitations:
Further validation studies are needed to confirm FOXA1's clinical utility across diverse tumor types.
The study does not address the potential role of FOXA1 in prognostic stratification and targeted therapy development.
Conclusion:
FOXA1 could serve as a valuable adjunct immunohistochemical marker in surgical pathology for aggressive prostate cancers, especially in the context of treatment resistance.
